Skip to content

A open label study to assess the efficacy of Injection sovateltide in patients with Elephantiasis.

A prospective, open-label study to assess the efficacy of sovateltide in filariasis patients with lower limb lymphedema - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090752
Enrollment
20
Registered
2025-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B948- Sequelae of other specified infectious and parasitic diseases

Interventions

Intervention1: Sovateltide: Sovateltide will be administered at a dose of 0.3 mcg per kg as an IV bolus over 1 minute at every 3 hours on days 1, 3, and 6. Total dose per day: 0.9 mcg per kg. Control

Sponsors

Janta Hospital and Maternity Center,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult male or female aged 18 to 80 years 2. Patient or his and her Legally Acceptable Representative willing to give informed consent before the study procedure. 3. Clinical diagnosis of lymphatic filariasis with WHO Stage 2 or 3 lower limb lymphedema 4. Ability to comply with study procedures

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding 2. History of malignancy or significant immunological disorders 3. Recent limb surgery or trauma, or a candidate for any surgical intervention during the study duration. 4. Evidence of any other major life threatening or serious medical condition, such as severe renal, hepatic, and cardiovascular disease, which would prevent completion of the study protocol, impair the assessment of outcome, or in which sovateltide therapy would be contraindicated or might cause harm to the patient. 5. The patient is participating in another interventional study

Design outcomes

Primary

MeasureTime frame
Number of patients with at least a 25% reduction in a diseased limb volume from baseline to Day 28.Timepoint: From baseline to Day 28.

Secondary

MeasureTime frame
Improvement in the Functional mobility assessment questionnaire for lower limb lymphoedema (LYMPH-ICF-LL) at Day 28 compared to baselineTimepoint: From baseline to Day 28;Improvement in the Functional mobility assessment questionnaire for lower limb lymphoedema (LYMPH-ICF-LL) at Day 28 compared to baselineTimepoint: From baseline to Day 28.;Proportion of patients with adverse events (AEs) and serious adverse events (SAEs)Timepoint: From baseline to Day 28

Countries

India

Contacts

Public ContactDr Manoj Kumar Pal

Janta Hospital and Maternity Center

manojpalvns@gmail.com9198677778

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026